Nucleic acid technology came of age during COVID-19 with biopharma firms developing, testing, mass producing, and shipping mRNA vaccines in record time. However, as the pandemic ebbs, the industry now needs to find ways of making DNA and RNA products more efficiently.

This is the view presented in a new study by scientists at Penn State who looked at purification methods used in nucleic acid manufacturing and found room for improvement.

A big problem is the fact that current chromatography and membrane separation techniques were developed with proteins in mind, says co-author Andrew Zydney, PhD, the Bayard D. Kunkle Chair and professor of chemical engineering at Penn State College of Engineering… Continue reading.